- Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drugPlus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker wil…Endpoints · 1mo ago↗ source
- Trodelvy misses in lung cancer, but Gilead and Merck have an HIV successGilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely braced for impact, according to Wall Street. The…Endpoints · 1mo ago↗ source
- Endpoints Women in Biopharma: Nominate for 2026Today we’re opening nominations for our eighth annual Women in Biopharma special project. Women in Biopharma is one of my favorite traditions at Endpoints. Each year, we take a hard look at the s…